Entry and competition in generic biologics

Article Abstract:

Policy makers are examining if generic biologics can be regulated like generic pharmaceuticals even if manufacturing biologics is more costly than developing pharmaceuticals. A theoretical model revealed that there will be fewer generic biolgics due to high cost of production and testing, which in turn, will lead to less competition and higher price. Promotion of generic competition in biologics is discussed.

Pharmaceutical Preparation Manufacturing, Market share, Generic Drugs, Company market share, Biopharmaceutics, Biopharmaceuticals

---

A primer on the economics of re-importation of prescription drugs

Article Abstract:

The implications of shifting from differential to standardized global pricing of prescription drugs on profitability of the global pharmaceutical indusrty is analyzed. It was investigated that the global pricing would have greater effects on Canada, Asia, and Europe than on the United States. The possibility that these regions would demand for lower prices as a consequence of uniform pricing is examined.

International aspects, Price control, Price regulations

---

An industrial organization perspective on the influenza vaccine shortage

Article Abstract:

Causes of influenza vaccine shortage in the United States, such as high cost, regulated price and tort liability, are investigated. Suppliers in the U.S. perceive that the cost of producing additional vaccines is higher than the benefits, which was proven false through a benefit/cost analysis. The advantages of immunization, and their importance in vaccine policy-making are analyzed.

Market information - general, Government domestic functions, Supply and demand, Influenza vaccines, Health policy

Similar abstracts:

• Abstracts: Industrial policy and competition policy: problems of interaction and lessons for Russia
• Abstracts: Bargaining and distribution in marriage. The economics of lesbian and gay families. The American family and family economics
• Abstracts: Corporate performance and Gazprom: problems and prospects. The merits of dual pricing of Russian natural gas. Rising energy prices in Moldova
• Abstracts: Mergers and acquisitions in the pharmaceutical and biotech industries. Dynamic competition in pharmaceuticals: cross-national evidence from new drug diffusion

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.